About Apcintex
Apcintex is a company based in Cambridge (United Kingdom) founded in 2014 was acquired by Centessa Pharmaceuticals in February 2021.. Apcintex has raised $17.5 million across 1 funding round from investors including Cambridge Enterprise, Centessa Pharmaceuticals and Touchstone Innovations. The company has 2 employees as of December 31, 2021. Apcintex operates in a competitive market with competitors including Editas Medicine, GBT, LogicBio, Modus Therapeutics and Kedrion, among others.
- Headquarter Cambridge, United Kingdom
- Employees 2 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Apcintex Limited
- Date of Incorporation 16 Jun, 2014
- Jurisdiction ALTRINCHAM, CHESHIRE, UNITED KINGDOM
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$17.5 M (USD)
in 1 rounds
-
Latest Funding Round
$17.5 M (USD), Series A
Feb 02, 2017
-
Investors
Cambridge Enterprise
& 3 more
-
Employee Count
2
as on Dec 31, 2021
-
Acquired by
Centessa Pharmaceuticals
(Feb 18, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Apcintex
Apcintex has successfully raised a total of $17.5M through 1 strategic funding round. The most recent funding activity was a Series A round of $17.5 million completed in February 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $17.5M
-
First Round
First Round
(02 Feb 2017)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2017 | Amount | Series A - Apcintex | Valuation | Medicxi , Touchstone Innovations |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Apcintex
Apcintex has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Cambridge Enterprise, Centessa Pharmaceuticals and Touchstone Innovations. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage life science focused VC firm investing in geographies such as Europe and the US
|
Founded Year | Domain | Location | |
|
Provider of intellectual property management and technology consulting services
|
Founded Year | Domain | Location | |
|
Creates, builds and invests in pioneering technology companies spun-out from Univs Cambridge, Oxford, and UCL
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Apcintex
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Apcintex
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Apcintex Comparisons
Competitors of Apcintex
Apcintex operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Editas Medicine, GBT, LogicBio, Modus Therapeutics and Kedrion, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for rare genetic diseases are developed using CRISPR technology.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for sickle cell disease treatment.
|
|
| domain | founded_year | HQ Location |
Viral vectors are developed for genetic and infectious disease treatments.
|
|
| domain | founded_year | HQ Location |
Polysaccharide-based drug for Sickle Cell Disease treatment is developed.
|
|
| domain | founded_year | HQ Location |
Plasma-derived therapies are developed for hemophilia and immune deficiencies.
|
|
| domain | founded_year | HQ Location |
Drug candidates for rare diseases are acquired, developed, and commercialized.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Apcintex
Frequently Asked Questions about Apcintex
When was Apcintex founded?
Apcintex was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Where is Apcintex located?
Apcintex is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Is Apcintex a funded company?
Apcintex is a funded company, having raised a total of $17.5M across 1 funding round to date. The company's 1st funding round was a Series A of $17.5M, raised on Feb 02, 2017.
How many employees does Apcintex have?
As of Dec 31, 2021, the latest employee count at Apcintex is 2.
What does Apcintex do?
Based on the work of Professor Jim Huntington (Cambridge Institute for Medical Research) and Dr Trevor Baglin (Cambridge University Hospitals), Apcintex has developed a new treatment that seeks to turn down the activity of a key natural anticoagulant pathway to produce normal blood clotting in patients with haemophilia. This means that the drug could potentially treat patients with all types of haemophilia, including those who develop antibodies to replacement factors.
Who are the top competitors of Apcintex?
Apcintex's top competitors include GBT, Editas Medicine and Kedrion.
Who are Apcintex's investors?
Apcintex has 4 investors. Key investors include Cambridge Enterprise, Centessa Pharmaceuticals, Touchstone Innovations, and Medicxi.